drugset
drugset / Trial / NCT04454567

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567 ↗

Phase 2 Terminated 2 enrolled Assembly Biosciences
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will explore the safety and antiviral activity of ABI-H0731 when added to a nucleos(t)ide reverse transcriptase inhibitor (NrtI) in participants who are partially virologically suppressed.

Timeline

Start
2020-11-11
Primary completion
2021-04-08
Completion
2021-04-08

Outcome

Outcome not reported

Stopped (Business): “Study stopped due to a change in the Sponsor's overall development strategy from treatment of chronic disease to finite, curative treatments, and is based partially on the advice and feedback from experts and regulators.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vebicorvir Small molecule 300 mg Oral
Background Entecavir Small molecule — —
Background Tenofovir disoproxil fumarate Small molecule — —
Background tenofovir alafenamide Small molecule — —

Indications

chronic hepatitis B virus infection